Surveillance de la résistance aux médicaments antituberculeux dans le monde: une analyse actualisée, 2007-2010
Vigilancia de la resistencia a los medicamentos contra la tuberculosis en todo el mundo: análisis actualizado, 2007-2010
Matteo Zignol*; Wayne van Gemert; Dennis Falzon; Charalambos Sismanidis; Philippe Glaziou; Katherine Floyd; Mario Raviglione
STOP TB Department, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland
OBJECTIVE: To present a global update of drug-resistant tuberculosis (TB) and explore trends in 1994-2010.
METHODS: Data on drug resistance among new and previously treated TB patients, as reported by countries to the World Health Organization, were analysed. Such data are collected through surveys of a representative sample of TB patients or surveillance systems based on routine drug susceptibility testing. Associations between multidrug-resistant TB (MDR-TB) and human immunodeficiency virus (HIV) infection and sex were explored through logistic regression.
FINDINGS: In 2007-2010, 80 countries and 8 territories reported surveillance data. MDR-TB among new and previously treated cases was highest in the Russian Federation (Murmansk oblast, 28.9%) and the Republic of Moldova (65.1%), respectively. In three former Soviet Union countries and South Africa, more than 10% of the cases of MDR-TB were extensively drug-resistant. Globally, in 1994 to 2010 multidrug resistance was observed in 3.4% (95% confidence interval, CI: 1.9-5.0) of all new TB cases and in 19.8% (95% CI: 14.4-25.1) of previously treated TB cases. No overall associations between MDR-TB and HIV infection (odds ratio, OR: 1.4; 95% CI: 0.7-3.0) or sex (OR: 1.1; 95% CI: 0.8-1.4) were found. Between 1994 and 2010, MDR-TB rates in the general population increased in Botswana, Peru, the Republic of Korea and declined in Estonia, Latvia and the United States of America.
CONCLUSION: The highest global rates of MDR-TB ever reported were documented in 2009 and 2010. Trends in MDR-TB are still unclear in most settings. Better surveillance or survey data are required, especially from Africa and India.
OBJECTIF: Présenter une mise à jour globale de la tuberculose (TB) pharmacorésistante et explorer les tendances de 1994 à 2010.
MÉTHODES: Les données relatives à la résistance aux médicaments des nouveaux patients de TB et de ceux traités antérieurement, telles que rapportées par les pays à l'Organisation mondiale de la Santé, ont été analysées. Ces données sont recueillies par des enquêtes représentatives auprès des patients ou des systèmes de surveillance basés sur des tests systématiques de sensibilité. Les associations entre la tuberculose ultrarésistante (TB-UR), le virus de l'immunodéficience humaine (VIH) et le sexe ont été explorées par régression logistique.
RÉSULTATS: En 2007-2010, 80 pays et 8 territoires ont fourni des données de surveillance. Parmi les cas nouveaux et traités antérieurement, la TB-UR était la plus élevée dans la Fédération de Russie (oblast de Mourmansk, 28,9%) et la République de Moldavie (65,1%), respectivement. Dans trois pays de l'ex-Union soviétique et en Afrique du Sud, plus de 10% des cas de TB-UR étaient ultra-résistants. Globalement, en 1994-2010, la multirésistance aux médicaments a été observée chez 3,4% (intervalle de confiance 95%, IC: 1,9 à 5,0) de tous les nouveaux cas de TB et 19,8% (IC 95%: 14,4 à 25,1) des cas de TB traités antérieurement. Aucune association générale entre la TB-UR et l'infection au VIH (rapports de cotes, OR: 1,4, IC 95%: 0,7 à 3,0) ou le sexe (OR: 1,1, IC 95%: 0,8 à 1,4) n'a été trouvée. Entre 1994 et 2010, les taux de TB-UR dans la population générale ont augmenté au Botswana, en République de Corée et au Pérou et diminué en Estonie, Lettonie et aux Etats-Unis d'Amérique.
CONCLUSION: Les taux mondiaux les plus élevés jamais signalés de TB-UR ont été documentés en 2009 et 2010. Les tendances de la TB-UR sont encore peu claires dans la plupart des paramètres. De meilleures données de surveillance ou d'enquête sont nécessaires, surtout en provenance d'Afrique et d'Inde.
OBJETIVO: Presentar una actualización global de la situación de la tuberculosis (TB) resistente a los medicamentos y analizar las tendencias entre 1994 y 2010.
MÉTODO Se analizaron los datos sobre la resistencia a los medicamentos entre los pacientes recién diagnosticados con TB y los que habían recibido tratamiento con anterioridad, en base a los informes que los países remitieron a la Organización Mundial de la Salud. Dichos datos se recopilaron a través de encuestas representativas a pacientes o mediante sistemas de vigilancia basados en pruebas rutinarias de sensibilidad a los medicamentos. A través de una regresión logística se analizaron las asociaciones existentes entre la tuberculosis multirresistente (TB-MDR), el virus de la inmunodeficiencia humana y el sexo.
RESULTADOS: Entre 2007 y 2010, 80 países y 8 territorios facilitaron sus datos de vigilancia. Los niveles más elevados de TB-MDR entre los casos recién diagnosticados y previamente tratados se registraron en la Federación de Rusia (Murmansk oblast, 28,9%) y la República de Moldova (65,1%), respectivamente. En tres de los países de la antigua Unión Soviética y en Sudáfrica, más de un 10% de los casos de TB-MDR fueron extremadamente resistentes. Entre 1994 y 2010 se observó en todo el mundo una multirresistencia de un 3,4% (95% de intervalo de confianza, IC: 1,9-5,0) en todos los casos nuevos de TB y de un 19,8% (95% IC: 14,4-25,1) en los casos de TB previamente tratados. No se observaron asociaciones globales entre la TB-MDR y la infección por el VIH (cociente de posibilidades, OR: 1,4; IC del 95%: 0,7-3,0) ni con el sexo (OR: 1,1; IC del 95%: 0,8-1,4). Entre los años 1994 y 2010, las tasas de TB-MDR en la población general aumentaron en Botswana, la República de Corea y Perú y descendieron en Estonia, Letonia y Estados Unidos de América.
CONCLUSIÓN: En 2009 y 2010 se registraron las tasas globales de MDR-TB más altas de la historia. Las tendencias de TB-MDR siguen sin quedar claras en la mayoría de los entornos. Es necesaria una mejor vigilancia o más datos procedentes de encuestas, especialmente en los casos de África e India.
Surveillance of resistance to drugs against tuberculosis (TB) is a cornerstone of any TB control programme. Surveillance data on drug resistance are needed to track the effectiveness of TB prevention and control activities; accurately forecast the need for patient treatments and plan accordingly; design standardized regimens for the treatment of drug-resistant TB; assess epidemiological trends; and promptly identify and respond to outbreaks of drug-resistant TB.1 Since 1994 the Global Project on Anti-Tuberculosis Drug Resistance Surveillance of the World Health Organization (WHO) has supported national TB control programmes worldwide in implementing drug resistance surveillance activities. Country data are routinely collected, analysed and disseminated to describe the global problem of drug-resistant TB.2-11
Patients whose mycobacteria are resistant to rifampicin, isoniazid and other anti-TB drugs require longer, expensive and more toxic treatment regimens and are less likely to be cured. This presents a formidable challenge to programmes, particularly in low-resource settings.12 Policy guidance on the programmatic management of drug-resistant TB13-15 and on how to control the transmission of resistant strains16 has been developed by WHO, and access to quality-assured second-line anti-TB drugs for the treatment of multidrug-resistant TB (MDR-TB) is facilitated through the Green Light Committee mechanism.17 The number of TB patients diagnosed and treated for MDR-TB, which is defined as TB caused by strains of Mycobacterium tuberculosis that are resistant to at least isoniazid and rifampicin,13 is increasing worldwide, but much remains to be done. In 2010, only 16% of the TB patients estimated to have MDR-TB were diagnosed and given appropriate treatment.11,12, Routine surveillance of drug resistance must be linked to patient care.
Over the past three years, WHO has been actively encouraging countries to establish continuous TB drug resistance surveillance systems based on routine drug susceptibility testing of all patients, with priority given to patients previously treated, who are at highest risk of developing drug resistance.18-20 Although limited laboratory capacity for drug susceptibility testing still represents a major obstacle to the establishment of surveillance systems in low-resource settings, new diagnostic tools such as line probe assays21 and Xpert MTB/RIF,22 combined with greater resources for laboratory strengthening, offer an unprecedented opportunity to scale up surveillance systems worldwide.
In this paper we evaluate the existing information on anti-TB drug resistance surveillance, with an emphasis on data reported in 2007-2010, after the publication of WHO's fourth global report on anti-TB drug resistance surveillance.8,9 We present a global overview of the extent of the problem of MDR-TB, explore associations between MDR-TB and human immunodeficiency virus (HIV) infection and sex, discuss time trends in drug resistance, and present available data on extensively drug-resistant TB (XDR-TB) - the latter defined as MDR-TB plus resistance to a fluoroquinolone and at least one second-line injectable agent (amikacin, kanamycin or capreomycin).13
Definitions and data collection
Drug resistance surveillance data are gathered following three main principles: (i) the data are representative of TB cases in the country or geographical setting under study; (ii) drug resistance among new TB cases is examined separately from drug resistance among previously treated TB cases; and (iii) laboratory methods for drug susceptibility testing are selected from among those that are recommended by WHO, with quality assurance for all laboratory processes conducted in cooperation with a partner supranational reference laboratory from the global network of 29 such laboratories.18,19,23,24
Drug resistance surveillance data are collected separately for new (previously untreated) and previously treated TB cases25 via special surveys or continuous surveillance. Special surveys measure drug resistance among a representative sample of notified cases of smear-positive pulmonary TB; continuous surveillance systems are based on routine diagnostic drug susceptibility testing in all bacteriologically-confirmed TB patients. Aggregated data from special surveys are collected through a standard data collection form, whereas continuous surveillance data are captured through "WHO['s ] global TB data collection system".26 WHO ascertains whether survey and continuous surveillance data meet quality and representativeness standards through criteria detailed elsewhere.10 The main indicator reported to estimate the frequency of MDR-TB is the proportion of confirmed TB cases with resistance to rifampicin and isoniazid. Data on resistance to any fluoroquinolone and second-line injectable agent among confirmed cases of MDR-TB are used to estimate the frequency of XDR-TB.
Data description, analysis and trends
The proportions of new and previously treated TB cases with MDR-TB and the proportion of MDR-TB cases with XDR-TB were calculated using the latest available national and subnational data. To derive global estimates for these indicators and to investigate the association between MDR-TB and HIV infection and sex, individual-level analyses were conducted using random-effects or robust standard errors logistic regression models to account for the clustering effect at the level of a country or territory. We used the I2 index27 to assess heterogeneity in country-level odds ratios (OR) before we combined these to obtain a pooled estimate. STATA version 11 (StataCorp. LP, College Station, United States of America) was used for all analyses.
Time trends in MDR-TB rates (annual number of new cases per 100 000 population)28 between 1994 and 2010 were calculated by multiplying the new TB case notification rates reported annually to WHO11 by the reported frequency of MDR-TB among new TB cases in the same setting and year. Exponential lines were fitted and the annual percentage change in the rate of MDR-TB was calculated for settings where anti-TB drug resistance had been measured in at least three different years.
Since the launch of the Global Project on Anti-tuberculosis Drug Resistance Surveillance in 1994, drug resistance data have been systematically collected and analysed from 127 countries, or 66% of WHO's 193 Member States. This includes 64 countries that have continuous surveillance systems based on routine diagnostic drug susceptibility testing of all patients. The remaining 63 countries have relied on special surveys of representative samples of patients. Of the 127 countries with surveillance information, 56 have data from one year only, 20 from two years, and 51 from three or more years (Fig. 1).
Most recent data, 2007-2010
Between 2007 and 2010, resistance to first-line anti-TB drugs was reported from 80 countries and 8 territories, 72 of which provided data from continuous surveillance and 16 from special surveys (Table 1, available at: http://www.who.int/bulletin/volumes/90/2/11-092585). Almost all countries (82/88, or 93%) reported nationwide data. Bangladesh (14 districts covering a population of 30 million), the Plurinational State of Bolivia, Chile, Colombia, El Salvador, Fiji, Kazakhstan, Lebanon, Mongolia, the Republic of Moldova, Rwanda and Sri Lanka provided continuous surveillance data on previously treated but not new TB cases. Subnational data were reported from Bangladesh, the Central African Republic, Indonesia, the Russian Federation (12 oblasts [administrative regions] and republics), Tajikistan and Uganda.
The proportion of new TB cases reported as showing multidrug resistance in these years ranged from 0% to 28.9%. Proportions exceeding 12% (in countries reporting more than 10 MDR-TB cases) were documented in Belarus (25.7%), Estonia (18.3%), several oblasts of the Russian Federation (with Murmansk having the highest level, 28.9%) and Tajikistan (Dushanbe city and Rudaki district, 16.5%).
The proportion of previously treated cases having MDR-TB ranged from 0% to 65.1%. Countries or subnational areas with proportions exceeding 50% included Belarus (60.2%), Lithuania (51.5%), the Republic of Moldova (65.1%), five oblasts of the Russian Federation, and Tajikistan (Dushanbe city and Rudaki district, 61.6%) (Table 1).
The largest country that conducted a nationwide survey in the reporting period was China, where 5.7% of new TB cases and 25.6% of previously treated cases were found to have multidrug resistance (Table 1).
Surveillance data on XDR-TB were reported from 38 countries and 3 territories, 34 of which routinely test all patients with MDR-TB for second-line anti-TB drug resistance. Only 6 out of 41 (15%) countries and territories reported more than 10 cases of XDR-TB; the proportion of MDR-TB cases that were extensively drug-resistant exceeded 10% in Estonia (19.7%), Latvia (15.1%), South Africa (10.5%) and Tajikistan (Dushanbe city and Rudaki district, 21.0%) (Table 2, available at: http://www.who.int/bulletin/volumes/90/2/11-092585).
Overall data, 1994-2010
The proportions of new and previously treated TB cases in the world that were multidrug resistant are shown in Fig. 2 and Fig. 3, respectively. Overall, when data from all countries and territories were combined, the global proportions of new and previously treated TB cases showing multidrug resistance were 3.4% (95% CI: 1.9-5.0) and 19.8% (95% CI: 14.4-25.1), respectively. Regional level estimates of the proportion of cases with MDR-TB are shown in Table 3.
XDR-TB has been identified in 77 countries globally, and 57 countries and 3 territories were able to report representative data from continuous surveillance or special surveys on the proportion of XDR-TB cases among MDR-TB cases. Combined data from all countries and territories showed that the proportion of MDR-TB cases with extensive drug resistance was 9.4% (95% CI: 7.4-11.6).
When data from 17 countries and 1 territory that reported drug resistance data stratified by HIV status were combined, the odds of having MDR-TB among HIV-positive cases were found to be 40% higher than among HIV-negative cases (pooled odds ratio, OR: 1.4; 95% CI: 0.7-3.0; OR consistent across countries, I2 = 23.2%; P-value = 0.19), but the difference was not significant. Thus, no association was noted between the presence of MDR-TB and HIV status.
A total of 58 countries and 2 special territories reported drug resistance surveillance data disaggregated by sex. Overall, when data from these settings were combined, the odds of having MDR-TB were found to be 10% higher among females than males (OR: 1.1; 95% CI: 0.8-1.4; OR heterogeneous across countries, I2 = 32.9%; P-value = 0.009), but the difference was not significant. Thus, no association was noted between the presence of MDR-TB and the sex of the patient.
Data on time trends in drug resistance were available from 71 countries and 751 country-year data points. Selected data to illustrate the diversity of trends in TB and MDR-TB worldwide are presented in Fig. 4. In a first group of countries, composed of Botswana, Peru and the Republic of Korea, the estimated notification rate of MDR-TB is increasing (+10.9%, +19.4% and +4.3% per year, respectively). In these countries, trends in notifications of new TB cases vary, with a clear increase in the Republic of Korea (+7.4% per year), a rather stable trend in Botswana (+0.3% per year) and a clear decline in Peru (-3.3% per year). A second group is composed of three Russian oblasts where TB notification rates are stable or decreasing. Although in these oblasts MDR-TB rates were on the rise until around 2005-2006, they have subsequently been falling in all three settings. In a third group of countries, composed of Estonia, Latvia and the United States, surveillance data suggest that both TB and MDR-TB rates have been falling for more than a decade. In the United States the rate of MDR-TB is falling even more quickly than the TB case notification rate.
In 2007-2010, several countries provided drug resistance surveillance data generated from continuous surveillance systems rather than special surveys, a change from previous reports.8,9 Of particular interest is a group of 12 countries that have succeeded in establishing continuous surveillance systems for previously treated TB cases: Bangladesh (14 districts covering a population of 30 million), the Plurinational State of Bolivia, Chile, Colombia, El Salvador, Fiji, Kazakhstan, Lebanon, Mongolia, the Republic of Moldova, Rwanda and Sri Lanka. This is the first step towards routine drug susceptibility testing for all TB cases and allows early identification of drug resistance in the population at greatest risk.18-20
Available data confirm that eastern Europe and central Asia continue to have the world's highest proportion of MDR-TB among TB cases. In 2007-2010 the highest proportions ever reported globally were documented in areas of the former Soviet Union; MDR-TB was reported among nearly 30% of new TB cases in the oblast of Murmansk in the Russian Federation and among 65% of previously treated TB cases in the Republic of Moldova. In a few other oblasts of the Russian Federation in the same region, levels of MDR-TB appear to be stabilizing or even decreasing, which confirms that addressing MDR-TB is feasible even in high-burden areas. Unfortunately, large parts of eastern Europe and central Asia still lack representative data. This applies to the whole of Kyrgyzstan and most of Azerbaijan, the Russian Federation, Tajikistan, Turkmenistan, Ukraine and Uzbekistan. With planned and ongoing surveys and improvements in continuous surveillance in these countries, major strides towards improving our understanding of the true burden of drug-resistant TB are expected in the near future.
China conducted its first nationwide survey in 2007. The survey, which confirmed previously published estimates8,9 based on extrapolation from subnational level data, represents a critical step towards addressing MDR-TB in one of the largest TB control programmes in the world. Whereas China has been able to conduct a nationwide survey, India and the Russian Federation - the other two large countries that, with China, contribute to more than 50% of the estimated global burden of MDR-TB - have only produced reliable subnational level data to date. To understand the magnitude of the MDR-TB problem and address it, nationwide surveillance systems should be established in all countries, with greater urgency in the highest burden settings.
Only 34 countries and settings have a system in place to routinely test all patients with MDR-TB for secondline anti-TB drug resistance. These are generally countries with established or emerging economies, as laboratory capacity for second-line drug susceptibility testing in resource-limited settings is still scarce.
The average proportions of MDR-TB cases among diagnosed TB cases detected in this study are consistent with previous reports.8,9 The lack of data on drug-resistant TB in most African countries is still a matter of major concern (Fig. 2 and Fig. 3). This situation should be urgently addressed, especially since the African Region accounts for over 80% of the TB cases among people living with HIV and since higher mortality from MDR-TB and XDR-TB has been documented in HIV-positive patients.29 The availability of new molecular technologies for diagnosing TB and detecting rifampicin resistance, including line probe assays and Xpert MTB/RIF, represent an unprecedented opportunity for countries with severely limited laboratory infrastructure to diagnose drug resistance more easily. Line probe assays permit safer transportation of specimens, require a lower workload than conventional culture and drug susceptibility tests, and reduce to two days the time needed for the diagnosis of MDR-TB.30,31 Xpert MTB/RIF is an automated nucleic acid amplification technology that detects rifampicin resistance in less than two hours. It is very simple to use and requires limited training and biosafety measures.22 A few countries have piloted the use of molecular technologies in drug resistance surveys,30,31 but data from surveys using exclusively those techniques are not yet available. Molecular technologies are expected to contribute substantially to surveillance of drug-resistant TB in lowresource settings in the future.
The analysis of risk factors for MDR-TB showed that the overall risk of harbouring MDR-TB strains is not influenced by sex. The sex distribution of patients with MDR-TB does not differ from that of patients with drug-susceptible TB. This finding is not surprising, since MDR-TB is a form of TB and has similar risk factors. Countries where an association is documented should be investigating the possible reasons.
Although an association between HIV infection and MDR-TB has been widely documented in hospital outbreaks of drug-resistant TB among people living with HIV,32-34 the population-based data gathered to date suggest that the relationship between multidrug resistance and HIV infection is not consistent across settings (although the available data are limited to a few countries). In addition, HIV status is unknown for large proportions of patients in these cohorts. Countries are still experiencing great difficulties in incorporating HIV testing in drug resistance surveys, as this requires strong collaboration between HIV and TB control programmes. Understanding the relationship between HIV infection and drug-resistant TB at the population level is critical to identify high-risk groups in need of additional support.
Trend analysis suggests that MDR-TB can be controlled once bold policy decisions are put into practice and the correct prevention and control measures are implemented. This is illustrated by recent findings reported from selected oblasts in the Russian Federation, where MDR-TB has been recognized as a serious problem since the time of the dissolution of the Soviet Union. In Arkhangelsk, Tomsk and Orel oblasts, TB case notifications are stable or decreasing, and although MDR-TB rates were increasing until 2005-2006, more recent data show a stabilizing (Arkhangelsk) or even declining trend (Tomsk and Orel). These settings, which have been treating many cases with MDR-TB in recent years, show that MDR-TB can be controlled even in places heavily affected by drug resistance. The same can be said for Estonia and Latvia, where TB and MDR-TB have been declining for more than a decade. In the United States, rates of MDR-TB are falling even more quickly than rates of TB. These last three countries have strong control programmes that have succeeded in reducing both susceptible and resistant forms of TB. In contrast, in the Republic of Korea, TB and MDR-TB notifications are both increasing, the latter more rapidly than the former. The diversity of treatment options and case management in the country, particularly in the large private health sector, may be facilitating the development of drug resistance.35 In Botswana TB notification rates have stabilized, whereas in Peru they have declined, in line with previous assessments.36 However, in both countries MDR-TB notification rates are showing a very marked increase.
Following 15 years of intensive effort, high-quality surveillance data on anti-TB drug resistance are available for two thirds of all countries in the world. These data show where MDR-TB rates are highest and demonstrate that in selected settings a proper response can alleviate the problem. At the same time, global trends in rates of MDR-TB remain unclear, largely because national representative data are lacking in many large countries, including India and several African countries. A better understanding of epidemiological trends in drug resistance at the global and national levels can be achieved only through repeated surveys and, ultimately, by establishing continuous surveillance based on routine drug susceptibility testing of all confirmed TB cases, with priority given to previously treated patients. Special studies are also needed to help us better understand the factors conducive to the development and spread of MDR-TB. If properly and intensively implemented and followed by appropriate treatment of all TB patients, new technologies can accelerate the response to the threat of drug resistance, save lives and reduce the burden TB imposes on individuals, households and communities.
Competing interests: None declared.
1. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis 1997;24(Suppl 1):S121-30. doi:10.1093/clinids/24.Supplement_1.S121 PMID:8994791
2. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization; 1997 (WHO/TB/97.229).
3. Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998;338:1641-9. PMID:9614254
4. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Report 2: Prevalence and trends. Geneva: World Health Organization; 2000 (WHO/CDS/TB/2000.278).
5. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A et al. Global trends in resistance to antituberculosis drugs. World Health Organization- International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001;344:1294-303. doi:10.1056/NEJM200104263441706 PMID:11320389
6. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Third global report. Geneva: World Health Organization; 2004 (WHO/HTM/TB/2004.343).
7. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A et al.; WHO/International Union Against Tuberculosis And Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-54. doi:10.1016/S0140-6736(06)69863-2 PMID:17174706
8. World Health Organization. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Fourth global report. Geneva, Switzerland: WHO, 2008 (WHO/HTM/TB/2008.394).
9. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K et al.; Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:1861-73. doi:10.1016/S0140-6736(09)603317 PMID:19375159
10. Multidrug and extensively drug-resistant TB (M/XDR-TB):2010global report on surveillance and response. Geneva: World Health Organization; 2010.
11. Global tuberculosis control. Geneva: World Health Organization; 2011 (WHO/HTM/TB/2011.16).
12. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. Geneva: World Health Organization; 2011 (WHO/HTM/TB/2011.3).
13. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: emergency update. Geneva: World Health Organization; 2008 (WHO/HTM/TB/2008.402; ISBN 978-92-4-154758-1).
14. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Geneva: World Health Organization; 2011 (WHO/HTM/TB/2011.6).
15. Falzon D, Jaramillo E, Schünemann H, Arentz M, Bayona J, Blanc L et al. WHO guidelines for the programmatic management of drugresistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28. doi:10.1183/09031936.00073611 PMID:21828024
16. WHO policy on TB infection control in health-care facilities, congregate settings and households. Geneva: World Health Organization; 2009 (WHO/HTM/TB/2009.419).
17. Green Light Committee Initiative of the Working Group on MDR-TB of the STOP TB Partnership. Annual report 2009. Geneva: World Health Organization; 2010 (WHO/HTM/TB/2010.14).
18. Guidelines for surveillance of drug resistance in tuberculosis. Fourth edn. Geneva: World Health Organization; 2009 (WHO/HTM/TB/2009.422).
19. Zignol M, van Gemert W, Falzon D, Jaramillo E, Blanc L, Raviglione M. Modernizing surveillance of anti-tuberculosis drug resistance: from special surveys to routine testing. Clin Infect Dis 2011;52:901-6. doi:10.1093/cid/cir081 PMID:21427397
20. The Global Plan to Stop TB 2011-2015. Geneva: Stop TB Partnership & World Health Organization; 2010.
21. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): policy statement. Geneva: World Health Organization; 2009. Available from: http://www.who.int/tb/features_archive/policy_statement.pdf. [accessed 28 October 2011]
22. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-15. doi:10.1056/NEJMoa0907847 PMID:20825313
23. Aziz MA, Wright A. The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases. Clin Infect Dis 2005;41(Suppl 4):S258-62. doi:10.1086/430786 PMID:16032561
24. Van Deun A, Wright A, Zignol M, Weyer K, Rieder HL. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis 2011;15:116-24. PMID:21276307
25. Treatment of tuberculosis guidelines. Fourth ed. Geneva: World Health Organization; 2009 (WHO/HTM/TB/2009.420).
26. The WHO global data collection system [Internet]. Geneva: World Health Organization; 2011. Available from: http://www.stoptb.org/tme/ [accessed 28 October 2011]
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. doi:10.1136/bmj.327.7414.557 PMID:12958120
28. United Nations. [database]. Population. New York: Department of Economic and Social Affairs, Population Division. Available from: http://esa.un.org/unpd/wpp/unpp/ [accessed August 2011]
29. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80. doi:10.1016/S0140-6736(06)69573-1 PMID:17084757
30. Rigouts L, Hoza AS, De Rijk P, Torrea G, Chonde TM, Basra D et al. Evaluation of the Genotype® MTBDRplus assay as a tool for drug-resistance surveys. Int J Tuberc Lung Dis 2011;15:959-65. doi:10.5588/ijtld.10.0515 PMID:21682972
31. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008;177:787-92. doi:10.1164/rccm.200709-1436OC PMID:18202343
32. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514-21. doi:10.1056/NEJM199206043262302 PMID:1304721
33. Moro ML, Gori A, Errante I, Infuso A, Franzetti F, Sodano L et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 1998;12:1095-102. doi:10.1097/00002030-19980900000018 PMID:9662207
34. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007;196(Suppl 1):S86-107. doi:10.1086/518665 PMID:17624830
35. Seung KJ, Bai GH, Kim SJ, Lew WJ, Park SK, Kim JY. The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis 2003;7:912-9. PMID:14552560
36. Suárez PG, Watt CJ, Alarcón E, Portocarrero J, Zavala D, Canales R et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis 2001;184:473-8. doi:10.1086/322777 PMID:11471105
Submitted: 24 June 2011
Revised version received: 7 October 2011
Accepted: 10 October 2011
Published online: 7 November 2011